Jpmorgan Chase & CO Harrow Health, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Harrow Health, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 43,887 shares of HROW stock, worth $2.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,887

Previous 74,764 41.3%

Holding current value

$2.01 Million

Previous $989,000 7.38%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$10.0 - $21.64 $308,770 - $668,178	-30,877 Reduced 41.3%	43,887 $916,000
Q1 2024 May 10, 2024	SELL	$9.3 - $13.23 $457,671 - $651,074	-49,212 Reduced 39.69%	74,764 $989,000
Q4 2023 Feb 12, 2024	BUY	$8.1 - $16.36 $377,978 - $763,423	46,664 Added 60.36%	123,976 $1.39 Million
Q3 2023 Nov 14, 2023	BUY	$14.03 - $22.08 $147,946 - $232,833	10,545 Added 15.79%	77,312 $1.11 Million
Q2 2023 Aug 11, 2023	BUY	$17.37 - $28.08 $225,532 - $364,590	12,984 Added 24.14%	66,767 $1.27 Million
Q1 2023 May 11, 2023	SELL	$13.84 - $21.46 $123,688 - $191,788	-8,937 Reduced 14.25%	53,783 $1.14 Million
Q4 2022 Feb 13, 2023	SELL	$10.28 - $14.78 $117,664 - $169,171	-11,446 Reduced 15.43%	62,720 $925,000
Q3 2022 Nov 14, 2022	SELL	$6.57 - $24.88 $40,293 - $152,589	-6,133 Reduced 7.64%	74,166 $896,000
Q2 2022 Aug 11, 2022	SELL	$5.75 - $7.74 $71,777 - $96,618	-12,483 Reduced 13.45%	80,299 $585,000
Q1 2022 May 11, 2022	SELL	$6.77 - $8.66 $89,289 - $114,216	-13,189 Reduced 12.45%	92,782 $634,000
Q4 2021 Feb 10, 2022	BUY	$8.5 - $12.0 $4,530 - $6,396	533 Added 0.51%	105,971 $915,000
Q3 2021 Nov 12, 2021	BUY	$6.99 - $10.6 $737,011 - $1.12 Million	105,438 New	105,438 $958,000

Others Institutions Holding HROW

# of Institutions

129

Shares Held

19.8M

Call Options Held

700K

Put Options Held

564K

View Full List

About HARROW HEALTH, INC.

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $1.24B
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

More about HROW

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Harrow Health, Inc. Transaction History